Viloxazine (brand name Qelbree) is a non-stimulant medication approved for the treatment of ADHD in children and adolescents aged 6 to 17. It offers a new approach to managing ADHD, especially for those who may not respond well to stimulant medications or experience undesirable side effects.
Mechanism of Action
Viloxazine (Qelbree) for ADHD works by modulating norepinephrine and serotonin in the brain. While stimulants primarily increase dopamine and norepinephrine, Viloxazine targets both norepinephrine and serotonin systems, helping improve attention, impulse control, and emotional regulation. This mechanism of action is thought to provide a steady, long-lasting effect without the immediate high or low associated with stimulant medications.
Non-Stimulant Option for ADHD
As a non-stimulant medication, Viloxazine (Qelbree) for ADHD is an attractive option for individuals who have concerns about the potential for stimulant misuse or side effects, such as insomnia or appetite loss. It offers an alternative for managing ADHD symptoms with a different pharmacological approach, helping reduce hyperactivity, impulsivity, and inattention.
Side Effects and Benefits
The side effect profile of Viloxazine is generally milder compared to stimulants. Some common side effects include decreased appetite, fatigue, and irritability, but these are often less severe than those experienced with stimulants. Additionally, Viloxazine does not carry the risk of abuse or addiction, making it a safer choice for long-term use.
In conclusion, Viloxazine (Qelbree) is an effective non-stimulant medication for ADHD that offers an alternative for individuals who need continuous symptom management without the side effects of stimulants.
Visit providers like ADHD Certify for personal consultations and expert guidance tailored to your unique situation.
For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medications for ADHD.
